The latest price target for Teva Pharmaceutical Indus (NYSE:TEVA) was reported by UBS on January 30, 2025. The analyst firm set a price target for $27.00 expecting TEVA to rise to within 12 months (a possible 52.20% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Teva Pharmaceutical Indus (NYSE:TEVA) was provided by UBS, and Teva Pharmaceutical Indus maintained their buy rating.

The last upgrade for Teva Pharmaceutical Industries Ltd happened on March 8, 2024 when JP Morgan raised their price target to $14. JP Morgan previously had an underweight for Teva Pharmaceutical Industries Ltd.

The last downgrade for Teva Pharmaceutical Industries Ltd happened on January 19, 2023 when Jefferies changed their price target from $10 to $12 for Teva Pharmaceutical Industries Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on January 30, 2025 so you should expect the next rating to be made available sometime around January 30, 2026.

While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a maintained with a price target of $30.00 to $27.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $17.74, which is out of the analyst’s predicted range.